正品控股有限公司(简称：正品控股)于2025年7月29日所递交的港股招股书满6个月，于2026年1月29日失效，递表时浤博资本有限公司为其独家保荐人。 招股书显示，正品控股主要在香港从事保健及美容补充品与产品的开发、销售、营销及分销。集团将产品的生产外包给供货商(包括制造商)并主要通过 万宁在香港的零售门市以集团自有品牌及第三方品牌分销集团的产品。根据弗若斯特沙利文的资料，按2024年保健及美容补充品与产品的零售值计算， 集团于香港所有本地保健及美容补充品与产品供货商中排名第七，市场占有率约为1.6%。 ...

智通财经APP获悉，正品控股有限公司(简称：正品控股)于2025年7月29日所递交的港股招股书满6个月，于2026年1月29日失效，递表时浤博资本有限公 司为其独家保荐人。 招股书显示，正品控股主要在香港从事保健及美容补充品与产品的开发、销售、营销及分销。集团将产品的生产外包给供货商(包括制造商)并主要通过 万宁在香港的零售门市以集团自有品牌及第三方品牌分销集团的产品。根据弗若斯特沙利文的资料，按2024年保健及美容补充品与产品的零售值计算， 集团于香港所有本地保健及美容补充品与产品供货商中排名第七，市场占有率约为1.6%。 | | 11/08/2025 整體協調人公告 - 委任（經修訂） PD | | --- | --- | | 29/07/2025 | 正品控股有限公司 29/07/2025 申請版本（第一次呈交） 全文檔案 [四] 多檔案 | ...

Core Viewpoint - 正品控股有限公司 is preparing for an IPO in Hong Kong, heavily reliant on a single customer, which poses significant risks to its business model and financial stability [1][3]. Group 1: Company Overview - 正品控股 specializes in the development, sales, marketing, and distribution of health and beauty supplements and products in Hong Kong, outsourcing production to suppliers [1]. - The company ranks seventh among local suppliers of health and beauty supplements in Hong Kong, with a market share of approximately 1.6% based on retail value in 2024 [1]. Group 2: Business Model and Revenue Sources - The retail business operates through the company's self-operated e-commerce platform and third-party online platforms, serving wholesale clients, general public customers, and corporate clients [2]. - The company has significant reliance on five major suppliers, with procurement amounts of approximately 6.2 million HKD, 22.2 million HKD, and 22.3 million HKD, accounting for about 86.3%, 77.3%, and 80.3% of total procurement, respectively [2]. Group 3: Customer Dependency and Financial Performance - The company has a critical dependency on a milk company, with revenues from this client amounting to approximately 38.5 million HKD, 84.0 million HKD, and 97.1 million HKD, representing about 89.1%, 76.7%, and 74.5% of total revenue during the historical periods [3]. - Financial projections indicate revenues of 43.2 million HKD, 109.6 million HKD, and 130.2 million HKD for fiscal years 2023, 2024, and 2025, with net profits of 11.3 million HKD, 35.5 million HKD, and 36.3 million HKD, respectively [3]. - The gross profit margins are projected to decline from 81.6% in 2023 to 75% in 2025, indicating a shrinking profit space and potential challenges in maintaining profitability and market competitiveness [3].